Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study.

The journal of sexual medicine - 1 Oct 2013

Shinghal Rajesh, Barnes Allison, Mahar Kelly M, Stier Brendt, Giancaterino Lisa, Condreay Lynn D, Black Libby, McCallum Stewart W

Abstract excerpt

AIM: To assess the efficacy and safety of the selective oxytocin receptor antagonist epelsiban in the treatment of premature ejaculation (PE). METHODS: Double-blind, randomized, parallel-group, placebo-controlled, stopwatch-monitored, phase 2, multicenter study (GSK557296; NCT01021553) conducted...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ATP Binding Cassette Transporter, Subfamily B
Share to Double-Blind Method

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Least-Squares Analysis

Share to Morpholines

Share to Patient Satisfaction

Share to Reaction Time

Share to Receptors, Oxytocin

Share to Sexual Behavior

Source

Identifiers

PMID: 23937679
DOI: 10.1111/jsm.12272

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23937679-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety and efficacy of epelsiban in the treatment of men with premature ejaculation: a randomized, double-blind, placebo-controlled, fixed-dose study.PMID 23937679Read ↗

No difference in 5-HTTLPR and Stin2 polymorphisms frequency between premature ejaculation patients and controls.Semantic proximity Read ↗

Next-Generation Pharmaceuticals: The Rise of Orodispersible Formulation Technology for Male Sexual HealthSemantic proximity Read ↗

Serotonin transporter (5-HTTLPR) genotypes and trinucleotide repeats of androgen receptor exert a combinatorial effect on hormonal milieu in patients with lifelong premature ejaculation.Semantic proximity Read ↗

Efficacy and Safety of Oral Gene III <sup>®</sup> L-Ergothioneine Capsules in Primary Dysmenorrhea: A Randomized, Double-Blind, Placebo-Controlled Clinical TrialSemantic proximity Read ↗

Effects of paroxetine on intravaginal ejaculatory latency time in Egyptian patients with lifelong premature ejaculation as a function of serotonin transporter polymorphism.Semantic proximity Read ↗

Population Pharmacokinetics of Elagolix in Healthy Women and Women with Endometriosis.Semantic proximity Read ↗

Effectiveness of Micro-Energy Therapies for Erectile Dysfunction: A Systematic Review and Network Meta-analysisSemantic proximity Read ↗

Electrical Muscle Stimulation for Conservative Management of Female Pelvic Floor Muscle Dysfunction: A Scoping ReviewSemantic proximity Read ↗

Helospectin from Heloderma Venom: A VIP‐Like Vasodilatory Peptide for Erectile Dysfunction and Clitoral Engorgement—A Theoretical Preclinical ProposalSemantic proximity Read ↗

A meta-analysis of the effects of the 5-hydroxytryptamine transporter gene-linked promoter region polymorphism on susceptibility to lifelong premature ejaculation.Semantic proximity Read ↗

Lack of precision in the reporting of sex and gender in cancer clinical trials with a PRO endpoint: a systematic reviewSemantic proximity Read ↗

Neurodoron® in patients with neurasthenia – A randomized, double-blind, placebo-controlled clinical trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.